US biotech firm Novavax on Monday said it had positive results from preclinical studies of a shot combining its influenza and COVID vaccine candidates.
US biotech firm Novavax on Monday said it had positive results from preclinical studies of a shot combining its influenza and COVID vaccine candidates.
